Relay Therapeutics price target lowered to $25 from $33 at Oppenheimer

Oppenheimer lowered the firm’s price target on Relay Therapeutics to $25 from $33 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company has been transparent about the fact that “we’ll need to wait until the end of this year for any real data.” At this point, there isn’t much one can do besides wait, especially absent any derisking data from competitors, Oppenheimer says.